Quantification of antiangiogenic and antivascular drug activity by kinetic analysis of DCE-MRI data

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 1, 2012, Pages 118-124

  Ferl, G Z ^a   Port, R E ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CONTRAST MEDIUM; GADOLINIUM;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CARDIOVASCULAR FUNCTION; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DRUG ACTIVITY; MATHEMATICAL MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MATHEMATICAL CONCEPTS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHARMACOKINETICS; PHARMACOLOGICAL PROCESSES;

EID: 84862598682     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.63     Document Type: Article

References (40)

1. Tabelow, K. & Whitcher, B. Special volume on magnetic resonance imaging in R. J Statistic Software 44, 1-6 (2011).
2. Westbrook, C., Roth, C. & Talbot, J. MRI in Practice 4th edn. (Blackwell Publishing, Chichester, UK, 2011).
3. Barrett, T., Brechbiel, M., Bernardo, M. & Choyke, P.L. MRI of tumor angiogenesis. J. Magn. Reson. Imaging 26, 235-249 (2007).
4. Hylton, N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J. Clin. Oncol. 24, 3293-3298 (2006).
5. O'Connor, J.P., Jackson, A., Parker, G.J., Roberts, C. & Jayson, G.C. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat. Rev. Clin. Oncol. 9, 167-177 (2012).
6. Quantitative Imaging Biomarkers Alliance. Profile: DCE-MRI Quantification 〈http://qibawiki.rsna.org/images/7/7b/DCEMRIProfile-v1-6-20111213. pdf〉(2011).
7. Hellman, R.N. Gadolinium-induced nephrogenic systemic fibrosis. Semin. Nephrol. 31, 310-316 (2011).
8. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
9. Yankeelov, T.E., Rooney, W.D., Li, X. & Springer, C.S. Jr. Variation of the relaxographic "shutter-speed" for transcytolemmal water exchange affects the CR bolus-tracking curve shape. Magn. Reson. Med. 50, 1151-1169 (2003).
10. Leach, M.O. et al.; Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br. J. Cancer 92, 1599-1610 (2005).
11. rd & Landaw, E.M. Multiexponential, multicompartmental, and noncompartmental modeling. I. Methodological limitations and physiological interpretations. Am. J. Physiol. 246, R651-R664 (1984).
12. Jacquez, J. Compartmental Analysis in Biology and Medicine 3rd edn. (BioMedware, Ann Arbor, MI, 1996).
13. Tofts, P.S. & Kermode, A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn. Reson. Med. 17, 357-367 (1991).
14. Atkinson, A., Abernethy, D., Daniels, C., Dedrick, R. & Markey, S. Principles of Clinical Pharmacology 2nd edn., Ch. 3 (Elsevier, Burlington, MA, 2007).
15. Tofts, P.S. et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J. Magn. Reson. Imaging 10, 223-232 (1999).
16. Rijpkema, M., Kaanders, J., Joosten, F., van der Kogel, A. & Heerschap, A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Mag. Reson. Imag. 14, 457-463 (2001).
17. Weinmann, H.J., Laniado, M. & Mützel, W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol. Chem. Phys. Med. NMR 16, 167-172 (1984).
18. Port, R.E., Knopp, M.V. & Brix, G. Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magn. Reson. Med. 45, 1030-1038 (2001).
19. Parker, G.J. et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn. Reson. Med. 56, 993-1000 (2006).
20. Ashton, E., Raunig, D., Ng, C., Kelcz, F., McShane, T. & Evelhoch, J. Scan-rescan variability in perfusion assessment of tumors in MRI using both model and data-derived arterial input functions. J. Magn. Reson. Imaging 28, 791-796 (2008).
21. Beal, Stuart L. and Sheiner, Lewis B. and Boeckmann, Alison and Bauer, Robert J. NONMEM User's Guides (1989-2009): Icon Development Solutions (Ellicott City, MD, 2009).
22. Port, R.E., Knopp, M.V., Hoffmann, U., Milker-Zabel, S. & Brix, G. Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. J. Magn. Reson. Imaging 10, 233-241 (1999).
23. Yang, C., Karczmar, G.S., Medved, M. & Stadler, W.M. Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations. Magn. Reson. Med. 52, 1110-1117 (2004).
24. Yankeelov, T.E. et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn. Reson. Imaging 23, 519-529 (2005).
25. Port, R.E., Bernstein, L.J., Barboriak, D.P., Xu, L., Roberts, T.P. & van Bruggen, N. Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab. Magn. Reson. Med. 64, 408-417 (2010).
26. Ferl, G.Z. & Port, R.E. A Two Compartment Tissue Model for Voxel-Wise Analysis of Malignant Tumors (International Society for Magnetic Resonance in Medicine, 2010). Workshop on Improving Cancer Treatment With Advanced MR, Santa Cruz, CA 〈http://www.ismrm.org/workshops/Cancer10/posters.htm〉.
27. Lüdemann, L., Grieger, W., Wurm, R., Wust, P. & Zimmer, C. Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn. Reson. Imaging 23, 833-841 (2005).
28. St Lawrence, K.S. & Lee, T.Y. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation. J. Cereb. Blood Flow Metab. 18, 1365-1377 (1998).
29. Buckley, D.L., Roberts, C., Parker, G.J., Logue, J.P. & Hutchinson, C.E. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging-initial experience. Radiology 233, 709-715 (2004).
30. Kershaw, L.E. & Cheng, H.L. Temporal resolution and SNR requirements for accurate DCE-MRI data analysis using the AATH model. Magn. Reson. Med. 64, 1772-1780 (2010).
31. Koh, T.S., Cheong, D.L. & Hou, Z. Issues of discontinuity in the impulse residue function for deconvolution analysis of dynamic contrast-enhanced MRI data. Magn. Reson. Med. 66, 886-892 (2011).
32. Huang, W. et al. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. Proc. Natl. Acad. Sci. USA 105, 17943-17948 (2008).
33. Evelhoch, J.L. Key factors in the acquisition of contrast kinetic data for oncology. J. Magn. Reson. Imaging 10, 254-259 (1999).
34. Cheng, H.L. Improved correlation to quantitative DCE-MRI pharmacokinetic parameters using a modified initial area under the uptake curve (mIAUC) approach. J. Magn. Reson. Imaging 30, 864-872 (2009).
35. Ferl, G.Z., Xu, L., Friesenhahn, M., Bernstein, L.J., Barboriak, D.P. & Port, R.E. An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab. Magn. Reson. Med. 63, 1366-1375 (2010).
36. Fan, X. & Karczmar, G.S. A new approach to analysis of the impulse response function (IRF) in dynamic contrast-enhanced MRI (DCEMRI): a simulation study. Magn. Reson. Med. 62, 229-239 (2009).
37. National Cancer Institute. Recommendations for MR measurement methods at 1.5-Tesla and endpoints for use in Phase 1/2a trials of anti-cancer therapeutics affecting tumor vascular function 〈imaging.cancer.gov/images/ documents〉.
38. Berry, L.R. et al. Quantification of viable tumor microvascular characteristics by multispectral analysis. Magn. Reson. Med. 60, 64-72 (2008).
39. Rose, C.J. et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn. Reson. Med. 62, 488-499 (2009).
40. O'Connor, J.P. et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br. J. Cancer 105, 139-145 (2011).